FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2148103659> ?p ?o ?g. }

• W2148103659 endingPage "4965" @default.
• W2148103659 startingPage "4958" @default.
• W2148103659 abstract "Purpose This randomized, noncomparative, parallel-group study was designed to evaluate the pathologic complete response (pCR) rate of combined doxorubicin plus paclitaxel (AP) and doxorubicin plus cyclophosphamide (AC) as neoadjuvant chemotherapy in patients with previously untreated breast cancer who were unsuitable for conservative surgery. Patients and Methods A total of 200 patients with T2-3, N0-1, M0 disease were randomly assigned in a 2:1 ratio to receive preoperative chemotherapy with either doxorubicin 60 mg/m 2 plus paclitaxel 200 mg/m 2 as a 3-hour infusion (AP) or doxorubicin 60 mg/m 2 plus cyclophosphamide 600 mg/m 2 (AC) every 3 weeks for 4 courses followed by surgery. Results A pCR (eradication of invasive carcinoma in tumor and in axillary lymph nodes) was found in 16% and 10% of patients in the AP and AC arms, respectively, by study center pathologists, and in 8% and 6% of patients, respectively, by independent pathologists. Patients with pCRs tended to have unifocal disease, tumors with negative hormonal receptor status, and less differentiation (Scarff, Bloom, and Richardson scale grade 3). Breast-conserving surgery was performed in 58% and 45% of patients in the AP and AC arms, respectively. An objective clinical response was achieved in 89% of patients in the AP arm and 70% in the AC arm. At a median follow-up of 31 months, disease-free survival (DFS) was higher in patients who reached pCR versus those without pCR (91% v 70%). Conclusion The encouraging pathologic and clinical responses of patients with breast cancer after neoadjuvant chemotherapy with doxorubicin plus paclitaxel warrant additional investigation of paclitaxel in the neoadjuvant setting of breast cancer management." @default.
• W2148103659 created "2016-06-24" @default.
• W2148103659 creator A5012336750 @default.
• W2148103659 creator A5012804079 @default.
• W2148103659 creator A5015900909 @default.
• W2148103659 creator A5018736489 @default.
• W2148103659 creator A5026275112 @default.
• W2148103659 creator A5052430948 @default.
• W2148103659 creator A5056565799 @default.
• W2148103659 creator A5070042596 @default.
• W2148103659 creator A5073063132 @default.
• W2148103659 creator A5080896131 @default.
• W2148103659 creator A5085474533 @default.
• W2148103659 creator A5089385974 @default.
• W2148103659 creator A5018360318 @default.
• W2148103659 date "2004-12-15" @default.
• W2148103659 modified "2023-09-26" @default.
• W2148103659 title "Randomized Parallel Study of Doxorubicin Plus Paclitaxel and Doxorubicin Plus Cyclophosphamide As Neoadjuvant Treatment of Patients With Breast Cancer" @default.
• W2148103659 cites W1919403884 @default.
• W2148103659 cites W1938913042 @default.
• W2148103659 cites W1948389446 @default.
• W2148103659 cites W1949597673 @default.
• W2148103659 cites W1955397179 @default.
• W2148103659 cites W1960713055 @default.
• W2148103659 cites W1966141442 @default.
• W2148103659 cites W1970569095 @default.
• W2148103659 cites W1984254136 @default.
• W2148103659 cites W1989644540 @default.
• W2148103659 cites W2050224717 @default.
• W2148103659 cites W2053184573 @default.
• W2148103659 cites W2086766680 @default.
• W2148103659 cites W2133764807 @default.
• W2148103659 cites W2138021040 @default.
• W2148103659 cites W2139510434 @default.
• W2148103659 cites W2157800681 @default.
• W2148103659 cites W2162760540 @default.
• W2148103659 cites W2164361217 @default.
• W2148103659 cites W2178225042 @default.
• W2148103659 cites W2227235589 @default.
• W2148103659 cites W4255152173 @default.
• W2148103659 cites W4294413353 @default.
• W2148103659 doi "https://doi.org/10.1200/jco.2004.02.122" @default.
• W2148103659 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15611510" @default.
• W2148103659 hasPublicationYear "2004" @default.
• W2148103659 type Work @default.
• W2148103659 sameAs 2148103659 @default.
• W2148103659 citedByCount "139" @default.
• W2148103659 countsByYear W21481036592012 @default.
• W2148103659 countsByYear W21481036592013 @default.
• W2148103659 countsByYear W21481036592014 @default.
• W2148103659 countsByYear W21481036592015 @default.
• W2148103659 countsByYear W21481036592016 @default.
• W2148103659 countsByYear W21481036592017 @default.
• W2148103659 countsByYear W21481036592018 @default.
• W2148103659 countsByYear W21481036592019 @default.
• W2148103659 countsByYear W21481036592020 @default.
• W2148103659 countsByYear W21481036592021 @default.
• W2148103659 countsByYear W21481036592022 @default.
• W2148103659 countsByYear W21481036592023 @default.
• W2148103659 crossrefType "journal-article" @default.
• W2148103659 hasAuthorship W2148103659A5012336750 @default.
• W2148103659 hasAuthorship W2148103659A5012804079 @default.
• W2148103659 hasAuthorship W2148103659A5015900909 @default.
• W2148103659 hasAuthorship W2148103659A5018360318 @default.
• W2148103659 hasAuthorship W2148103659A5018736489 @default.
• W2148103659 hasAuthorship W2148103659A5026275112 @default.
• W2148103659 hasAuthorship W2148103659A5052430948 @default.
• W2148103659 hasAuthorship W2148103659A5056565799 @default.
• W2148103659 hasAuthorship W2148103659A5070042596 @default.
• W2148103659 hasAuthorship W2148103659A5073063132 @default.
• W2148103659 hasAuthorship W2148103659A5080896131 @default.
• W2148103659 hasAuthorship W2148103659A5085474533 @default.
• W2148103659 hasAuthorship W2148103659A5089385974 @default.
• W2148103659 hasConcept C121608353 @default.
• W2148103659 hasConcept C126322002 @default.
• W2148103659 hasConcept C126894567 @default.
• W2148103659 hasConcept C141071460 @default.
• W2148103659 hasConcept C143998085 @default.
• W2148103659 hasConcept C2776694085 @default.
• W2148103659 hasConcept C2776755627 @default.
• W2148103659 hasConcept C2777292972 @default.
• W2148103659 hasConcept C2777649267 @default.
• W2148103659 hasConcept C2778292576 @default.
• W2148103659 hasConcept C2781303535 @default.
• W2148103659 hasConcept C530470458 @default.
• W2148103659 hasConcept C71924100 @default.
• W2148103659 hasConcept C90924648 @default.
• W2148103659 hasConceptScore W2148103659C121608353 @default.
• W2148103659 hasConceptScore W2148103659C126322002 @default.
• W2148103659 hasConceptScore W2148103659C126894567 @default.
• W2148103659 hasConceptScore W2148103659C141071460 @default.
• W2148103659 hasConceptScore W2148103659C143998085 @default.
• W2148103659 hasConceptScore W2148103659C2776694085 @default.
• W2148103659 hasConceptScore W2148103659C2776755627 @default.
• W2148103659 hasConceptScore W2148103659C2777292972 @default.
• W2148103659 hasConceptScore W2148103659C2777649267 @default.
• W2148103659 hasConceptScore W2148103659C2778292576 @default.
• W2148103659 hasConceptScore W2148103659C2781303535 @default.

• next